Press release
Chengdu, China, September 1, 2026 — Anticancer Bioscience (ACB) received regulatory clearance from China’s National Medical Products Administration (NMPA) to initiate a first-in-human Phase 1 clinical trial of JMBI-001, its lead MYC synthetic-lethal drug candidate.
JMBI-001 is an investigational oral small-molecule drug discovered through ACB’s proprietary SYMPLEXTM platform. It is designed to exploit cellular dependencies associated with deregulated MYC activity in cancer. Preclinical studies demonstrated antitumor activity across multiple tumor models, reduced tumor vascularization, and evidence of antitumor immune activation.
The Phase 1 trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in patients with advanced cancers.
A key translational question is whether tolerable drug exposures produce target-proximal pharmacodynamic effects and downstream biological responses. The resulting safety, exposure, and biomarker data will guide dose selection and subsequent clinical development.
ACB is preparing to initiate the trial in collaboration with clinical investigators in China. JMBI-001 remains investigational, and its safety and efficacy in patients have not yet been established.
About Anticancer Bioscience
Anticancer Bioscience (ACB) is a Chengdu-based biotechnology company developing innovative anticancer therapies that exploit cancer-specific dependencies. Its drug-development programs translate discoveries in cancer biology and synthetic lethality into novel therapeutic approaches.